Immuno-Biological Laboratories
4570.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥1.0bn | ¥970m | ¥817m | ¥795m | ¥648m | ¥603m |
| Operating income | ¥281m | ¥209m | ¥104m | ¥57mr | −¥122m | −¥241m |
| Ordinary income | ¥301m | ¥210m | ¥125m | −¥150m | −¥243m | −¥311m |
| Net income (owners) | ¥329m | ¥249m | ¥187m | −¥290m | −¥259m | −¥319m |
| Total assets | ¥2.2bn | ¥1.8bn | ¥1.6bn | ¥1.4bn | ¥1.7bn | ¥1.8bn |
| Net assets / equity | ¥1.8bn | ¥1.5bn | ¥1.3bn | ¥1.1bn | ¥1.4bn | ¥1.6bn |
| Operating cash flow | ¥301m | ¥183m | ¥134m | ¥26m | −¥93m | −¥194m |
| EPS (basic) | ¥35.33 | ¥26.74 | ¥20.05 | ¥-31.1 | ¥-27.78 | ¥-34.23 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 4
| Period | Form | Figures |
|---|---|---|
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 190 figures · EDINET |
25 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Cosmetics | ¥3m | −¥609,000 |
| Immunity Related | ¥1.0bn | ¥282m |
| Total | ¥1.0bn | ¥281m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.